Indications and Usage Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg and Ozempic (semaglutide) tablets 4 mg or 9 mg are indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes Ozempic injection is indicated: to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes and established CV disease to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease Ozempic tablets are indicated: to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes who are at high risk for these events Important Safety Information for Ozempic WARNING: RISK OF THYROID C-CELL TUMORS In rodents, semaglutide causes dose-dependent and treatment-duration- dependent thyroid C-cell tumors at clinically relevant exposures
Pevec, T., et al
Qu alimentos contienen glutatin
reduced cardiac damage following myocardial stress Collateral pathway activation: BPC-157 demonstrated upgrading of minor vessels to compensate for major vessel occlusion Central Nervous System Research Neuroprotection Studies Research in traumatic brain injury and stroke models demonstrated neuroprotective effects from both peptides[14,15]: BPC-157 : Reduced lesion volumes in cortical injury
The GLP-1 receptor activation contributes to glucose control by stimulating insulin release, suppressing glucagon secretion when blood glucose is elevated, and slowing gastric emptying
